Screener
BridgeBio Pharma BBIO Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Commitments and contingencies (Note 7) | ||
| Redeemable convertible noncontrolling interests | (1,018) | (570) |
| Stockholders’ deficit: | ||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 205,867,350 shares issued and 195,284,352 shares outstanding as of June 30, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | 206 | 202 |
| Treasury stock, at cost; 10,582,998 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 | (533,279) | (323,276) |
| Additional paid-in capital | 2,155,318 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (7) | 12 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's preferred stock, shares authorized?
- BridgeBio Pharma (BBIO) reported preferred stock, shares authorized of $25M in Q2 2026.
- What does preferred stock, shares authorized mean?
- Preferred Stock, Shares Authorized
Ask your AI about BridgeBio Pharma's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude